Research Guide
KLOW Blend
A four-compound research blend for gut, skin and immune barrier studies.
Overview
KLOW is a curated blend combining four regenerative research compounds — KPV, LL-37, orexin-A precursors and GHK-Cu derivatives. Investigated for synergistic effects on gut, skin and immune barrier integrity.
Mechanism of action
KPV is an anti-inflammatory research compound fragment of α-MSH. LL-37 is the only human cathelicidin antimicrobial research compound. Together with the supporting research compounds, KLOW targets multiple barrier-repair pathways in parallel.
Reference range (research literature)
Research protocols use 1–2mg of the total blend daily, subcutaneously, in cycles of 4–8 weeks.
Half-life
Mixed (component-dependent), typically 2–6 hours.
Reconstitution
Reconstitute the 80mg vial with 4ml bacteriostatic water. Each 0.1ml = 2mg of total blend.
Comparisons
vs KPV alone
KLOW adds antimicrobial and regenerative pathways KPV does not cover.
Commonly researched stacks
- BPC-157 / TB-500 (extended repair protocols)
Frequently asked
Can the components be split?
No — they are co-lyophilised in fixed ratios.
Why a blend?
Research literature investigates multi-pathway approaches to barrier repair.
Disclaimer: Information on this page is for research and educational use only. Research compounds sold by AUSPEPS are not approved for human consumption and are intended exclusively for laboratory research.